Market Cap
$105.27 Billion
USD as of Jan. 1, 2024
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
AbbVie | $285.06 B |
Roche | $240.44 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Top 1-year algo backtest: +313.24%
$10,000 in May 2023 would now be $41,324 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Gilead Sciences, Inc., is a pharmaceutical and biotechnology company focusing on antiviral drugs to treat HIV, hepatitis B, hepatitis C, and influenza, notably producing and commercializing the blockbuster drugs Harvoni and Sovald. Besides, Gilead conducts research to develop a pipeline of new drugs and treatments and it also considers the acquisition of other blockbuster drugs.
Gilead Sciences, Inc. has the following listings and related stock indices.
Stock: NASDAQ: GILD
Stock: BCBA: GILD
Stock: BMV: GILD
Stock: Bovespa: GILD34
Stock: FSX: GIS
Stock: MTA: GILD
The market capitalization of a company, more simply referred to as "market cap", is the total market value of a publicly traded company's outstanding shares. It is often considered as a key indicator of what a company is worth.